WO2023030315A1 - 一种用于艾滋病病毒感染基因治疗的基因序列构建体 - Google Patents

一种用于艾滋病病毒感染基因治疗的基因序列构建体 Download PDF

Info

Publication number
WO2023030315A1
WO2023030315A1 PCT/CN2022/115831 CN2022115831W WO2023030315A1 WO 2023030315 A1 WO2023030315 A1 WO 2023030315A1 CN 2022115831 W CN2022115831 W CN 2022115831W WO 2023030315 A1 WO2023030315 A1 WO 2023030315A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
hiv
hiv infection
sequence
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/115831
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
吴昊泉
孙保贞
党颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanglin Biotechnology Hangzhou Co Ltd
Original Assignee
Kanglin Biotechnology Hangzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanglin Biotechnology Hangzhou Co Ltd filed Critical Kanglin Biotechnology Hangzhou Co Ltd
Priority to CA3230810A priority Critical patent/CA3230810A1/en
Priority to CN202280056353.6A priority patent/CN118382699A/zh
Priority to JP2024513543A priority patent/JP2024532453A/ja
Priority to US18/687,689 priority patent/US20240352096A1/en
Priority to AU2022337765A priority patent/AU2022337765A1/en
Priority to EP22863450.7A priority patent/EP4397764A4/en
Publication of WO2023030315A1 publication Critical patent/WO2023030315A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the invention belongs to the technical field of gene therapy/biomedicine, and in particular relates to a gene sequence construct used for gene therapy of AIDS virus (HIV) infection.
  • the gene sequence construct can be used for gene therapy against HIV infection.
  • the gene sequence construct can be used in vivo and in vitro to express polytropic neutralizing antibody proteins with broad-spectrum and high-efficiency neutralization of HIV virus activity, and can be used for clinical research on gene therapy drugs for HIV infection delivered by recombinant viruses or non-viral vectors and new drug development.
  • AIDS immunodeficiency syndrome
  • human immunodeficiency virus human immunodeficiency virus
  • HIV human immunodeficiency virus
  • the present invention creates a series of anti-HIV infection gene therapy constructs based on recombinant viral vectors. For example, a variety of broad-spectrum neutralizing antibodies against HIV, single-chain antibody variable fragments (scFv) of neutralizing antibodies against human CD4 receptors, and HIV membrane fusion inhibitory polypeptides are combined into a simple and efficient expression framework.
  • scFv single-chain antibody variable fragments
  • these gene sequence constructs for HIV infection gene therapy include one or more gene coding sequences of single-chain antibody molecules (including nanobodies) without constant regions that have the ability to inhibit HIV infection and one or more genes that have the ability to inhibit HIV infection.
  • the single-chain antibody molecule of the above-mentioned gene sequence construct comprises a heavy chain variable region and/or a light chain variable region.
  • said light chain variable region comprises a light chain variable region of a kappa or lambda light chain.
  • the above-mentioned gene sequence construct comprises two or more gene coding sequences of single-chain antibody molecules without constant regions that have the ability to inhibit HIV infection.
  • the above-mentioned gene sequence construct may contain two or more gene coding sequences of polypeptides capable of inhibiting HIV infection. These polypeptides consist of 2-50 amino acid residues.
  • the fusion protein molecule encoded by a single gene and comprising an anti-HIV infection single-chain antibody molecule without a constant region and a polypeptide has four or more action targets.
  • the fusion protein molecule encoded by a single gene and comprising an anti-HIV infection single-chain antibody molecule without a constant region and a polypeptide has five or more action targets.
  • the fusion protein molecule encoded by a single gene and comprising an anti-HIV infection single-chain antibody molecule without a constant region and a polypeptide has six or more action targets.
  • the fusion protein molecule encoded by a single gene and comprising an anti-HIV infection single-chain antibody molecule without a constant region and a polypeptide has three or more action targets.
  • the coding sequence of the linker polypeptide is directly or indirectly concatenated.
  • the gene sequence construct described in any one of the above which comprises two or more gene coding sequences of single-chain antibody molecules without constant regions that have the ability to inhibit HIV infection, wherein the gene coding sequences of the antibody molecules It is directly or indirectly connected in series through the coding sequence of the linker polypeptide.
  • the gene sequence construct described in any one of the above, wherein the gene coding sequence of one or more single-chain antibody molecules without constant regions that has the ability to inhibit HIV infection comprises anti-HIV-1-gp160 (or its splicing Gene coding sequences of antibody molecules that cut products gp120 and gp41).
  • the gene sequence construct described in any one of the above, wherein the gene coding sequence of one or more single-chain antibody molecules without constant regions with the ability to inhibit HIV infection comprises antibody molecules that bind to human CD4 receptor sites gene coding sequence.
  • the gene sequence construct according to any one of the above, wherein the one or more gene coding sequences of polypeptides capable of inhibiting HIV infection include gene coding sequences of polypeptides inhibiting fusion of HIV and CD4+ T cell membranes.
  • the gene sequence construct described in any one of the above, which comprises two or more gene coding sequences of single-chain antibody molecules without constant regions that have the ability to inhibit HIV infection and one or more single-chain antibody molecules that have the ability to inhibit HIV infection The gene coding sequence of the polypeptide, wherein the gene coding sequences of the two or more single-chain antibody molecules without constant regions that have the ability to inhibit HIV infection include anti-HIV-1-gp160 (or its spliced products gp120 and The gene coding sequence of the antibody molecule of gp41) and the gene coding sequence of the antibody molecule binding to the human CD4 receptor site, and the gene coding sequence of one or more polypeptides with the ability to inhibit HIV infection include the ability to inhibit HIV and CD4 + Gene coding sequence of polypeptide for T cell membrane fusion.
  • the gene sequence construct described in any one of the above which includes (i) light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of anti-HIV-1-gp160 (or its cleavage products gp120 and gp41) monoclonal antibody and Gene coding sequences of heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3), (ii) light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) and heavy chain complementarity determining regions of monoclonal antibodies that bind to the human CD4 receptor site (HCDR1, HCDR2 and HCDR3) gene coding sequence, (iii) gene coding sequence of a polypeptide that inhibits fusion between HIV and CD4+ T cell membrane, wherein the coding sequences of light chain and heavy chain of the antibody can be passed through the linker in no particular order
  • the coding sequence of the polypeptide is directly or indirectly concatenated.
  • the gene sequence construct described in any one of the above which includes (i) light chain variable region (VL) and heavy chain variable region (VL) of anti-HIV-1-gp160 (or its cleavage products gp120 and gp41) monoclonal antibody region (VH), (ii) the gene coding sequence of the light chain variable region (VL) and the heavy chain variable region (VH) of the monoclonal antibody binding to the human CD4 receptor site, (iii) the inhibitory
  • the gene sequence construct described in any one of the above which additionally comprises a promoter located in the gene coding sequence of the single-chain antibody molecule without the constant region having the ability to inhibit HIV infection and the gene coding sequence of the polypeptide having the ability to inhibit HIV infection upstream.
  • the gene sequence construct described in any one of the above which additionally comprises a secretory signal peptide coding sequence located in the gene coding sequence of a single-chain antibody molecule without a constant region with the ability to inhibit HIV infection and a gene with a polypeptide capable of inhibiting HIV infection upstream of the coding sequence.
  • the gene sequence construct described in any one of the above, which comprises the gene coding sequence of the first single-chain antibody molecule without the constant region with the ability to inhibit HIV infection, and the second one without the constant region with the ability to inhibit HIV infection which are selected from:
  • VL2 and VH2 are the variable region fragments of the light chain and heavy chain of the first antibody molecule respectively;
  • VL1 and VH1 are the variable region fragments of the light chain and heavy chain of the second antibody molecule respectively;
  • linker is the linker Polypeptide;
  • peptide inhibitor is a polypeptide that inhibits HIV infection (eg, a polypeptide that inhibits fusion of HIV with CD4+ T cell membranes).
  • VL2-linker-VH2-linker-VL1-linker-VH1 is VL2-linker-VH2-linker-VL1-linker-VH1, or a construct formed by arranging the combinations of VL2 and VH2 or VL1 and VH1 in different sequences.
  • the above gene sequence construct is VL2-linker-VH2-linker-VL1-linker-VH1-linker-peptide inhibitor, or the combination of VL2 and VH2 or VL1 and VH1 is arranged in different order of constructs.
  • linker polypeptide selected from the following amino acid sequences: GGGGS, (GGGGS) 2 , (GGGGS) 3 , (GGGGS) 4 , (GGGGS) 5 , (GGGGS) 6 , and (GGGGS) 7 , or other optional linker polypeptide sequences.
  • the polypeptide that inhibits the membrane fusion of HIV and CD4+ T cells can be selected from the membrane fusion inhibitory polypeptides P52, C34, T20 and the like.
  • the sequence of the membrane fusion inhibitory polypeptide P52 includes SEQ ID NO: 5 or its homologous sequence having at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical; the polypeptide sequence of C34 Comprising SEQ ID NO: 6 or having at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical homologous sequences thereto; the polypeptide sequence of T20 comprising SEQ ID NO: 7 or having therewith Homologous sequences that are at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical.
  • the present invention also provides a viral vector genome comprising any of the aforementioned constructs and a corresponding viral vector system comprising the genome.
  • the above-mentioned viral vector system may be a lentiviral vector system or an adeno-associated virus vector system.
  • the lentiviral vector system can include the viral vector genome of any of the above-mentioned constructs and other nucleotide sequences encoding and expressing the packaging components required for the production of lentiviruses, which will be introduced into production cells to produce The lentiviral particle of the construct genome.
  • the adeno-associated virus vector system can comprise the viral vector genome of any of the above-mentioned constructs and other nucleotide sequences encoding and expressing the packaging components required for the production of adeno-associated virus, which will be introduced into production cells to produce Adeno-associated virus particles of the construct genome described above.
  • Any virus particle produced as described above which comprises the genome of any of the constructs described in the foregoing, can express anti-HIV neutralizing antibody molecules after transduction of cells, and can be used for administration to patients to inhibit or Prevent HIV infection.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the above-mentioned virus particle, and a pharmaceutically acceptable carrier or diluent, or cells transduced by the above-mentioned lentivirus particle in vitro, These include, but are not limited to, transduced muscle cells, liver cells, or CD4+ T cells.
  • One of the above virus particles or the pharmaceutical composition comprising the above virus particles can be used for injection into the body to express two or more target antibody molecular proteins, which can infect humans by binding to HIV
  • the multiple binding sites involved in different steps of CD4+ T cells can efficiently and broadly block HIV's infection process of human CD4+ T cells, so as to be used for gene therapy of HIV infection, so as to achieve the goal of treating HIV-infected patients long-term treatment.
  • the present invention provides a method for inhibiting HIV infection, comprising administering the above-mentioned virus particle or pharmaceutical composition to cells.
  • the cells mentioned therein include muscle cells, liver cells, or CD4+T cells and the like.
  • the above-mentioned cells can be transduced in vitro or in vivo with one of the above-mentioned virus particles or pharmaceutical composition.
  • the present invention provides a method of treating HIV infection in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a viral particle or pharmaceutical composition as described above.
  • the subjects mentioned therein include HIV early-infected persons or HIV-infected persons who are receiving cocktail drug therapy or HIV-infected persons who are resistant to cocktail drug therapy.
  • the method of administering the drug to the above-mentioned subject is through intramuscular injection of one of the above-mentioned virus particles or the pharmaceutical composition.
  • one of the viral particles or pharmaceutical compositions described above or CD4+ T cells transduced therethrough is injected intravenously.
  • Virosomes and pharmaceutical compositions injected into the body by the method described above can express anti-HIV protein molecules with multiple targets and be secreted into the blood, can act on multiple nodes of HIV infection, and can Effectively block the route of HIV infection and effectively avoid the loss of the ability to inhibit HIV infection due to escape mutations in HIV, so as to achieve long-term (for example, drug effects lasting one year or several years) against HIV infection with a single injection ) and even permanent healing effects.
  • Antibody-like molecules composed of multiple single-chain antibody variable region fragments (scFv) based on the above-mentioned expression framework were delivered to mice by lentivirus and adeno-associated virus vectors, showing effective blood drug concentrations and strong In vitro cytology HIV-1 virus neutralizing activity, as well as the broad-spectrum neutralizing ability to CXCR4 and CCR5 two tropic viruses at the same time, is a technical route for the development of anti-HIV broad-spectrum neutralizing antibody gene therapy drugs with great potential.
  • scFv single-chain antibody variable region fragments
  • the scope of application of the present invention includes various forms of anti-HIV gene therapy based on the genetic expression of broad-spectrum neutralizing antibodies.
  • Figure 1 Schematic representation of the mature molecular structure of a tritropic anti-HIV neutralizing antibody expected to exist in a monomeric form.
  • Fig. 2 Schematic diagram of gene sequence composition of tritropic anti-HIV neutralizing antibody.
  • Figure 3 Schematic representation of the mature molecular structure of amphotropic anti-HIV neutralizing antibodies expected to exist in monomeric form.
  • FIG. 1 Schematic diagram of the gene sequence composition of the amphotropic anti-HIV neutralizing antibody.
  • Fig. 5 Schematic diagram of gene constructs in which the gene sequences of amphitropic (KL-BsHIV01-02) or tritropic (KL-BsHIV01-003-02) anti-HIV neutralizing antibodies are cloned into lentiviral vectors.
  • Figure 7 Schematic diagram of the gene construct in which the gene sequence of amphitropic (KL-BsHIV01-02) or tritropic (KL-BsHIV01-003-02) anti-HIV neutralizing antibody is cloned into an adeno-associated virus vector.
  • FIG. 8 Map of the latest generation of adeno-associated virus vector pAAV-MCS-CBH-WPRE used in the present invention.
  • Figure 9 Detection of anti-HIV neutralizing antibodies by Western blot analysis.
  • M prestained protein size marker; 1 and 6, purified Flag-KL-BsHIV01-003-02; 2 and 7, purified KL-BsHIV01-003-02; 3-5 and 8-10, purified Flag-KL-BsHIV01-003-02 was digested with enterokinase under different conditions.
  • the primary antibody is rabbit Anti-KL-BsHIV01-003-02 polyclonal antibody; 6-10, the primary antibody is mouse Anti-DYKDDDDK (Flag-tag).
  • FIG. 11 Expression of different doses of anti-HIV neutralizing antibody adeno-associated virus gene therapy vector in BALB/c mice after intramuscular injection. The levels of anti-HIV neutralizing antibodies secreted into mouse sera were determined by ELISA.
  • FIG. 12 Expression of different doses of anti-HIV neutralizing antibody adeno-associated virus gene therapy vector in BALB/c mice after intramuscular injection. Neutralizing activity of anti-HIV neutralizing class antibodies secreted into mouse serum.
  • bNAb Broadly neutralizing antibodies
  • bNAb Broadly neutralizing antibodies
  • CD4+ T cells CD4+ T cells
  • the infectious activity of the virus on CD4+ T cells represents a promising approach to prevent or combat HIV-1 infection.
  • the specific mechanism of its production is not clear.
  • Most HIV-1 infected persons can only produce non-neutralizing antibodies.
  • no research has successfully induced the production of broad-spectrum neutralizing antibodies in healthy subjects through standard immunization methods. .
  • recombinantly derived broadly neutralizing antibodies against the HIV-1 virus can effectively reduce the viral load in a patient and help control, if not completely eliminate HIV from the body. The infection develops into AIDS.
  • neutralizing antibodies from recombinant sources can also greatly reduce toxic and side effects, and at the same time increase patients' compliance with medication.
  • recombinant broad-spectrum neutralizing antibodies can be used not only as vaccine replacement products in specific situations to prevent the occurrence of HIV infection, but also as antiviral drugs in different disease stages.
  • Anti-HIV infection gene therapy drugs delivered by recombinant viruses or non-viral vectors can stably express neutralizing antibodies or antibody-like macromolecules in the body for a long time in the form of genome integration or non-integration, and can be effective for a long time or even for a lifetime after one treatment, greatly reducing the Production and use costs of macromolecular antibody drugs.
  • the present invention adopts a multiphilic antibody molecular structure, that is, the antigen binding region is composed of two or more single-chain variable region fragments (scFv) of monoclonal broad-spectrum neutralizing antibodies connected in series by a linker polypeptide (linker) .
  • scFv single-chain variable region fragments
  • linker linker polypeptide
  • the specific embodiment includes constructing a series of antibody molecular gene constructs comprising amphotropic/tritropic antibody single-chain variable region fragments (scFv), and cloning them into recombinant adeno-associated virus and recombinant lentiviral vectors. Then package the corresponding adeno-associated virus and lentivirus in 293T cells, and infect 293T cells and differentiated and undifferentiated muscle cell lines with a certain biological titer virus. The antibody molecules produced in the cell supernatant are subjected to quantitative and qualitative detection, and their neutralizing activity against the HIV-1 wild virus strain is tested in the infection activity analysis of the HIV-1 wild virus strain and the virus-sensitive reporter gene cell line TZM-bl .
  • scFv amphotropic/tritropic antibody single-chain variable region fragments
  • Antibody can be an immunoglobulin, antigen-binding fragment, or a protein molecule derived therefrom that can specifically recognize and bind an antigen (eg, HIV-1 gp41 antigen).
  • Antibody in the present invention is a broad definition covering various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, polytropic antibodies (e.g., amphiphilic antibodies, triphilic antibodies), and Antibody fragments, so long as they have specific antigen-binding activity. Examples of specific antibodies include intact immunoglobulins as well as antibody variants and fragments that retain binding affinity for the antigen.
  • antibody fragments include, but are not limited to, variable region fragments (Fv), antigen-binding fragments (e.g., Fab, Fab', Fab'-SH, or F(ab') 2 produced after proteolysis), single-chain antibody Molecules (eg, scFv), diabodies, nanobodies, and polytropic antibodies formed from combinations of antibody fragments.
  • Fv variable region fragments
  • Antibody fragments include antigen-binding fragments produced by modification of intact antibodies or antigen-binding fragments synthesized de novo using recombinant DNA techniques.
  • Single-chain antibody is a molecule obtained by genetic engineering, which contains one or more antibody light chain variable regions (VL) and heavy chain variable regions (VH), and the fragments are connected in series by a suitable linker polypeptide become a fused single-chain molecule.
  • VL antibody light chain variable regions
  • VH heavy chain variable regions
  • the tandem sequence of VL and VH in the single-chain antibody molecule usually does not affect its antigen-binding function, so the single-chain antibody composed of two tandem methods (VL-VH or VH-VL) will be used.
  • An antibody can have one or more antigen combining sites. When there is more than one antigen binding site, these binding sites may be the same or different. For example, a naturally occurring immunoglobulin has two identical antigen-binding sites, while Fab fragments produced from papain hydrolysis of immunoglobulins have only one antigen-binding site, and amphotropic single-chain antibodies (scFv) Has two distinct antigen-binding sites.
  • scFv amphotropic single-chain antibodies
  • immunoglobulin Normally, a naturally occurring immunoglobulin consists of light and heavy chains linked by disulfide bonds. Immunoglobulin genes include gamma, alpha, delta, epsilon, mu, lambda, and kappa constant region genes as well as a myriad of immunoglobulin variable region genes. There are two types of light chains, lambda and kappa. There are five main types of heavy chains ( ⁇ , ⁇ , ⁇ , ⁇ , ⁇ ), which determine the functional classification of antibody molecules, namely IgG, IgA, IgD, IgE, and IgM.
  • Each heavy and light chain contains a constant region and a variable region.
  • VH denotes the variable region of an antibody heavy chain, including the heavy chain variable region of an antigen-binding fragment Fv, scFv, or Fab.
  • VL denotes the variable region of an antibody light chain, including the light chain variable region of an antigen-binding fragment Fv, scFv, or Fab. In the following examples, VH and VL work together to specifically recognize and bind antigens.
  • VH and VL comprise three spaced hypervariable regions, also called complementarity determining regions (CDRs), as well as a framework region.
  • CDRs complementarity determining regions
  • the sequences of the framework regions of different light and heavy chains are relatively conserved within the same species.
  • the framework regions of an antibody determine the positions of the CDRs in the three-dimensional structure.
  • Complementarity determining regions are primarily responsible for binding to the epitope of an antigen.
  • the three complementary determining regions on the light chain are designated LCDR1, LCDR2, and LCDR3 from N-terminus to C-terminus, respectively.
  • the three complementary determining regions on the heavy chain are designated HCDR1, HCDR2, and HCDR3 from N-terminus to C-terminus, respectively.
  • the protein sequences of VH and VL in the present invention include not only the sequences disclosed in the following examples, but also any other sequences carrying their functional fragments, or at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical homologous sequences.
  • the constant region fragment of an antibody is a relatively stable region of the amino acid sequence of the immunoglobulin except the variable region with a large change in the amino acid sequence near the N-terminus, including the constant domain in the antigen-binding fragment (located at the N-terminus of the hinge region, including light chain constant domain and heavy chain constant domain) and the constant domain of the crystallizable fragment of the heavy chain (called the Fc fragment, located C-terminal to the hinge region).
  • the Fc fragment generally refers to the last two constant region domains of immunoglobulins IgA, IgD, and IgG or the last three constant region domains of IgE and IgM.
  • the Fc fragment may also include part or all of the hinge region sequence at its N-terminus.
  • Anti-HIV-1 neutralizing antibody or antigen-binding fragment specifically binds HIV-1 envelope proteins (eg, to gp41), thereby inhibiting HIV-1 envelope-associated biological Function (eg, ability to bind target receptor).
  • HIV-1 envelope proteins eg, to gp41
  • HIV-1 envelope-associated biological Function eg, ability to bind target receptor.
  • anti-HIV-1 neutralizing antibodies or antigen-binding fragments reduce the infectious titers of HIV-1 strains of different tropisms on cells.
  • Amphotropic or multiphilic antibody This type of antibody is a recombinant molecule composed of two or more different antigen-binding domains, so it can bind two or more different antigenic determinants.
  • Amphotropic or multiphilic antibodies include molecules composed of two or more different antigen-binding domains linked by chemical synthesis or genetic engineering. Antigen binding domains can be linked via a linker polypeptide. The antigen binding domain can be a monoclonal antibody, an antigen binding fragment (eg, scFv or Fab), or a combination of antigen binding domains of different origin.
  • Linker polypeptide used to connect two protein molecules or fragments into a continuous single fusion molecule, for example, in the following examples, two or more antibody molecules or antigen-binding fragments (for example, scFv) are connected into two or a multiphilic antibody molecule with multiple antigen-binding sites; or just connect the light chain variable region (VL) and heavy chain variable region (VH) of an antibody into a single-chain antigen-binding sequence; or Antibody molecules or antigen-binding fragments are linked together with other effector molecules, for example, antigen-binding fragment scFv is linked with HIV-1 membrane fusion inhibitory polypeptide to form a fusion protein.
  • VL light chain variable region
  • VH heavy chain variable region
  • Linker polypeptides are usually rich in glycine (Gly or G) to increase the flexibility of the linker, and serine (Ser or S) or threonine (Thr or T) to increase solubility, for example, the ones used in some of the examples below (GGGGS) n connectors of different lengths, n can be 1 or more.
  • the linker polypeptide sequence used in the embodiment is not limited to this, and also includes other optional linker polypeptide sequences.
  • Antigenic determinant A specific chemical group or polypeptide sequence on a molecule, which is antigenic, that is, it can stimulate a host-specific immune response.
  • An antibody specifically binds to a specific epitope on a polypeptide, such as an antibody that specifically binds to an epitope on gp41 in the examples below.
  • HIV-1 envelope protein The HIV-1 envelope protein is first synthesized as a precursor protein of 845-870 amino acid residues in size, called HIV gp160. gp160 forms a homotrimer in the host cell, is glycosylated, and undergoes cleavage to remove the signal peptide, and then is cleaved by a protease in the cell at the position of 511/512 amino acid residues to generate gp120 and gp41 polypeptide chains. Gp120 and gp41 remain associated in a homotrimer as a gp120/gp41 protomer.
  • Mature gp120 consists of amino acid residues 31-511 of the HIV-1 envelope protein and is a highly N-glycosylated protein that constitutes the domain of the HIV-1 envelope protein trimer exposed on the envelope surface the vast majority. gp120 is responsible for binding to the human CD4 cell receptor as well as coreceptors such as the chemokine receptors CCR5 or CXCR4. gp41 is composed of 512-860 amino acid residues of the HIV-1 envelope protein, including an envelope inner domain, a transmembrane domain, and an envelope outer domain. The extra-envelope domain of gp41 includes 512-644 amino acid residues, and it combines with gp120 to form a protomer, which jointly constitutes a homotrimer of HIV-1 envelope protein.
  • the protruding extraenvelope domain of the HIV-1 envelope protein trimer undergoes several structural rearrangements, from a closed structure that escapes antibody recognition before fusion with the host cell membrane to binding to human CD4 cell receptors and coreceptors.
  • HIV Membrane Fusion Inhibiting Polypeptide Membrane fusion between virus and host cell is a key step for HIV to infect cells. After the glycoprotein gp120/gp41 homotrimer on the HIV envelope binds to the human CD4 cell receptor and co-receptor, it undergoes several steps of structural changes, culminating in the insertion of the integrated gp41 trimer on the HIV envelope into the host cell membrane , to complete the fusion of the virus and host cell membranes, and the genetic material of HIV enters the cell.
  • the HIV membrane fusion inhibitory polypeptide binds to the envelope protein of the virus, thereby preventing it from undergoing structural changes necessary for the fusion of the virus and the host CD4 cell membrane, thereby preventing HIV from infecting the CD4 cell.
  • HIV membrane fusion inhibitory polypeptides used in the present invention include the P52, C34, T20 sequences disclosed in the following examples or have at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical homolog
  • Gene sequence construct a vector composed of a recombinant polynucleotide sequence, which is formed by linking an expression control sequence with a nucleic acid sequence to be expressed.
  • the expression vector contains sufficient cis-acting elements, and the other expression elements are provided by the host cell.
  • Expression vectors include all vectors of the present invention, such as plasmids and viruses (eg, recombinant lentiviruses and recombinant adeno-associated viruses) carrying integrated recombinant polynucleotide sequences.
  • the vector carries nucleic acid sequences (DNA or RNA) that allow it to replicate in a host cell, such as an origin of replication, one or more selectable marker genes, and other genetic structures disclosed in the present invention.
  • Viral vectors are recombinant nucleic acid vectors that carry at least part of the nucleic acid sequences from one or more viruses.
  • the viral vector comprises one or more nucleic acid sequences encoding the disclosed antibody or antigen-binding fragment that specifically binds HIV-1 gp160 to neutralize HIV-1.
  • the viral vector may be a recombinant adeno-associated virus (AAV) vector or a recombinant lentiviral vector.
  • AAV adeno-associated virus
  • viral vectors are replication-deficient vectors, which require other auxiliary plasmids or vectors carrying gene functions or components necessary for viral replication to be amplified and packaged in cells to produce virus particles. The purified and prepared virus vector or virus particle will not be replicated and amplified in the host cell during the treatment of the patient.
  • HIV is a virus that attacks the body's immune system. It takes the most important CD4 T lymphocytes in the human immune system as the main attack target, destroys the cells in large quantities, and makes the human body lose its immune function. Many patients with acute HIV infection experience flu-like symptoms 2-4 weeks after infection, which may last from days to weeks. There is a large amount of HIV in the blood of patients in the acute infection stage, which is highly infectious. Then enter the asymptomatic chronic infection period, also known as the HIV incubation period. However, the HIV in the patient's body is still active and continues to proliferate, which will spread HIV. The average incubation period of HIV in the human body is 8 to 9 years.
  • HIV-infected persons can live and work for many years without any symptoms. However, if HIV-infected persons do not receive any anti-HIV infection treatment, they will develop into the most serious HIV infection period after the incubation period, that is, the AIDS stage. AIDS patients have a very high viral load and can easily infect HIV to other people. The immune system is severely damaged, and the human body is prone to various diseases and malignant tumors, with a high mortality rate.
  • the goals of treatment at this stage are: to maximize and sustainably reduce the viral load; to obtain immune function reconstruction and maintenance of immune function; to improve the quality of life; to reduce HIV-related morbidity and mortality.
  • the currently commonly used anti-HIV infection method is antiretroviral combination therapy (ie, cocktail therapy), which greatly improves the curative effect of anti-HIV, and significantly improves the quality of life and prognosis of patients.
  • cocktail therapy antiretroviral combination therapy
  • cocktail therapy such as the need to maintain long-term medication compliance, and the gradual emergence of HIV drug-resistant strains still cause long-term economic and social burdens to the majority of AIDS patients, and the obvious decline in quality of life and obvious pain.
  • a broad-spectrum neutralizing antibody with HIV-1 neutralizing activity isolated from a small number of elite infected individuals can efficiently and broadly bind to the surface glycoprotein of HIV virus and neutralize the infection activity of HIV virus on human CD4+ T cells , represents a promising approach to prevent or combat HIV-1 infection.
  • neutralizing antibodies from recombinant sources can also greatly reduce toxic and side effects, and at the same time increase patients' compliance with medication.
  • the only anti-HIV neutralizing antibody approved for clinical use is Ibalizumab targeting the CD4 receptor on the surface of human T cells.
  • the infectious activity of +T cells has shown excellent curative effect on multi-drug resistant patients with HIV infection.
  • the specific broad-spectrum neutralizing antibody only targets a single epitope of a single viral protein (HIV-gp160), and the escape phenomenon caused by virus mutation is still unavoidable. Much higher than the small molecule anti-HIV drugs, the combined drug has no advantage.
  • the present invention aims to develop amphotropic and polytropic neutralizing antibodies or antibody-like macromolecular drugs, cover multiple targets to avoid escape from virus mutations, and genotype protein broad-spectrum neutralizing antibodies or antibody-like macromolecular drugs. A breakthrough in the development of anti-HIV broad-spectrum neutralizing antibody drugs.
  • Anti-HIV infection gene therapy drugs delivered by recombinant viruses or non-viral vectors long-term stable expression of neutralizing antibodies or antibody-like macromolecules in the body in a genome-integrated or non-integrated manner, and a long-term treatment (for example, the drug effect lasts for one year) or several years) or even lifetime, greatly reducing the cost of production and use of macromolecular antibody drugs.
  • the structure of the anti-HIV neutralizing antibody used in the present invention and class antibody molecule is:
  • Triphilic anti-HIV neutralizing antibody scFv molecule from the N-terminal to the C-terminal of the protein molecule are respectively - signal peptide - anti-HIV-gp41 broad-spectrum neutralizing antibody single-chain variable region fragment (VL-(ggggs) n linker-VH)-(ggggs) n linker-single-chain variable region fragment of anti-human CD4 antibody (VL-(ggggs) n linker-VH)-(ggggs) n linker—HIV membrane fusion inhibiting short peptide.
  • the coding sequence of the indicated gene is expressed in the cell and then translated into protein, which is then secreted out of the cell.
  • Figure 1 shows the mature molecular structure of the expected anti-HIV neutralizing antibody
  • Figure 2 shows the gene structure.
  • Amphotropic anti-HIV neutralizing antibody scFv molecule from the N-terminal to the C-terminal of the protein molecule are respectively - signal peptide - anti-HIV-gp41 broad-spectrum neutralizing antibody single-chain variable region fragment (VL-(ggggs) n linker-VH)-(ggggs) n linker-single-chain variable region fragment of anti-human CD4 antibody (VL-(ggggs) n linker-VH).
  • VL-(ggggs) n linker-VH broad-spectrum neutralizing antibody single-chain variable region fragment
  • VL-(ggggs) n linker-VH broad-spectrum neutralizing antibody single-chain variable region fragment
  • VL-(ggggs) n linker-VH broad-spectrum neutralizing antibody single-chain variable region fragment
  • VL-(ggggs) n linker-VH broad-spectrum neutralizing antibody single-chain variable region fragment
  • the anti-HIV-gp41 broad-spectrum neutralizing antibody single-chain variable region fragment (scFv) sequences are: signal peptide (see SEQ ID NO: 1 for the protein sequence); anti-HIV-1-gp41-MPER antibody (10E8v4-5R+ 100cF)-scFv (see SEQ ID NO:2 for the protein sequence); the single-chain variable region fragment scFv (see SEQ ID NO:3 for the protein sequence) of anti-human CD4 antibody (Ibalizumab), HIV membrane fusion inhibitory short peptide P52 (protein The sequence is shown in SEQ ID NO: 4), HIV membrane fusion inhibitory short peptide C34 (protein sequence is shown in SEQ ID NO: 5), HIV membrane fusion inhibitory short peptide T20 (protein sequence is shown in SEQ ID NO: 6).
  • Anti-HIV amphotropic neutralizing antibody molecule KL-BsHIV01-02 comprising anti-HIV neutralizing antibody 10E8v4-5R+100cF–scFv (see SEQ ID NO: 7 for the protein sequence) (see SEQ ID NO: 8 for the DNA sequence )( Figure 4).
  • Anti-HIV triphilic neutralizing antibody molecule KL-BsHIV01-003-02 (see SEQ ID NO: 9 for protein sequence) (see SEQ ID NO for DNA sequence) comprising anti-HIV neutralizing antibody 10E8v4-5R+100cF–scFv :10) (Fig. 2).
  • the lentiviral vector comprises: 5' LTR, wherein the promoter region of LTR is replaced with CMV promoter; ⁇ packaging signal; retroviral export element RRE; cPPT; promoter CBH; nucleotides; post-transcriptional regulatory elements are WPRE; PPT; ⁇ U3 3'LTR; and poly(A) signal.
  • the neutralizing antibody gene expression framework ( Figure 2 and Figure 4) designed in this example was synthesized by Nanjing GenScript Biotechnology Co., Ltd. and the CBH promoter (see SEQ ID NO: 22 for the sequence), through the well-known methods in the art.
  • the method of homologous recombination was cloned into the multi-cloning site AgeI/EcoRV on the lentiviral vector backbone pKL-kan-lenti-CBH-WPRE ( Figure 6).
  • the sequence information was confirmed by sequencing, and the plasmids were named pKL -Kan-lenti-CBH-KL-BsHIV01-02 (see SEQ ID NO: 12 for the sequence), pKL-Kan-lenti-CBH-KL-BsHIV01-003-02 (see SEQ ID NO: 13 for the sequence).
  • the HIV neutralizing antibody gene expression framework CBH-KL-BsHIV01-02 and CBH-KL-BsHIV01-003-02 present in pKL-Kan-lenti-CBH-KL-BsHIV01 were divided into multi-fragment
  • the method of recombinant connection is cloned between the multiple cloning sites AgeI/SalI of the latest generation of adeno-associated virus vector pAAV-MCS-CBH-WPRE (see SEQ ID NO: 14) currently used (see Figure 8).
  • the adeno-associated virus vector includes: AAV2 ITR; promoter CBH; polynucleotide encoding HIV neutralizing antibody fragment; WPRE and SV40 poly(A) signal; AAV2 ITR.
  • the plasmids were named pAAV-CBH-KL-BsHIV01-02-WPRE (see SEQ ID NO: 15 for the sequence) and pAAV-CBH-KL-BsHIV01-003-02-WPRE (see SEQ ID NO: 16 for the sequence).
  • HIV neutralizing antibody gene therapy lentiviral vectors in 293T cell line package of.
  • the lentiviral vector transfected cell culture supernatant
  • the lentiviral vector was harvested, and firstly in the benchtop On a hanging bucket centrifuge, centrifuge at 4000rpm at room temperature for 5 minutes to remove cell debris, and then centrifuge at 10000g at 4°C for 4 hours to obtain a pellet of virus particles. After removing the centrifuged supernatant, add 1 mL of DMEM complete medium to the pellet of virus particles, and resuspend with a micro-injector Virus particles, and the prepared virus resuspension was subpackaged and frozen at -80°C for later use.
  • the HIV neutralizing antibody gene therapy AAV vector was packaged in 293T cell line with AAV expression vector (pAAV-CBH-KL-BsHIV01-02-WPRE, pAAV-CBH-KL-BsHIV01-003-02-WPRE).
  • HIV neutralizing antibody gene therapy AAV vector, capsid plasmid (AAV2/8, its nucleotide sequence shown in SEQ ID NO:20) and packaging plasmid (pHelper, its nucleotide sequence shown in SEQ ID NO:20) with the HIV neutralizing antibody gene therapy that constructs in the embodiment ID NO: 21) were mixed and co-transfected 293T cells at the same time, and the HIV neutralizing antibody gene therapy vector AAV was packaged in the 293T cell line.
  • the transfection method is the transient transfection of eukaryotic cells mediated by PEI cationic polymer
  • the PEI cationic polymer is the PEI-Max transfection reagent purchased from Polysciences (purchased from Polysciences, catalog number: 24765-1), and the transfection operation refers to the production
  • the standard operation recommended by the manufacturer was carried out, and the transfection scale was 15cm cell culture dish. 7 hours after transfection, the supernatant was discarded and replaced with 25ml of toxin-producing medium.
  • the packaged lentiviral vectors pKL-Kan-lenti-CBH-KL-BsHIV01-02 and pKL-Kan-lenti-CBH-BsHIV01-003-02 were used to infect 293T cells according to different MOI. After 48 hours, the supernatant and some cells were collected. The copy number of lentiviral vector infection was detected by probe method.
  • VCN copy number
  • TZM-bl cells at 2E4 cells/well. Take 50 ⁇ L of antibody expression supernatants from different cells with a VCN of 1, dilute different times, mix with 50 ⁇ L HIV virus pAD-8 or pNL4-3, incubate at 37°C for 30 min, add to TZM-bl cells, add only pAD-8 or pNL4-3 The wells of pNL4-3 were negative control (NC), and the wells without HIV virus were Blank. At 24 hours, discard the supernatant, add 100 ⁇ L of cell lysate, collect the lysed cells after 10 minutes, and centrifuge at 8000 rpm for 5 minutes.
  • TZM-bl cells were plated at 2E4 cells/well. Take the cell expression supernatants of KL-BsHIV01, KL-BsHIV01-02, KL-BsHIV01-003, and KL-BsHIV01-003-02 with the same MOI of 8E4vg, and take the amphotropic antibody KL-BsHIV01 containing the Fc segment respectively The cell expression supernatant of amphotropic antibody KL-BsHIV01-02 and triptropic antibody KL-BsHIV01-003-02 without the Fc segment in the same volume as triptropic antibody KL-BsHIV01-003, and 50 ⁇ L HIV virus pAD After mixing -8 or pNL4-3, incubate at 37°C for 30 minutes, and add to TZM-bl cells.
  • Wells with only pAD-8 or pNL4-3 are negative controls (NC), and wells without HIV virus are Blank.
  • N negative controls
  • discard the supernatant add 100 ⁇ L of cell lysate, collect the lysed cells after 10 minutes, and centrifuge at 8000 rpm for 5 minutes.
  • RLU relative light unit
  • the HIV neutralizing antibody AAV gene therapy vector (pAAV-CBH-KL-BsHIV01-02-WPRE, pAAV-CBH-KL-BsHIV01-003-02-WPRE) was injected intramuscularly into the hind limbs of mice at a dose of 2E11vg/mouse respectively. thigh muscles. Blood was drawn every 1 week, and serum was separated.
  • TZM-bl cells were plated at 2E4 cells/well. Take the same volume of serum dilution and mix them with 50 ⁇ L of HIV virus pAD-8 or pNL4-3, incubate at 37°C for 30 minutes, and add them to TZM-bl cells.
  • the wells with only pAD-8 or pNL4-3 are negative controls ( NC), the well without HIV virus is Blank.
  • NC negative controls
  • the well without HIV virus is Blank.
  • discard the supernatant add 100 ⁇ L of cell lysate, collect the lysed cells after 10 minutes, and centrifuge at 8000 rpm for 5 minutes. Add 100 ⁇ L of firefly luciferase assay reagent to 50 ⁇ L of lysed cells.
  • the lentiviral plasmid carrying Flag-KL-BsHIV01-003-02 was transiently transfected into 293T cells, and the supernatant was collected after 48 hours, and the Flag was purified with anti-DYKDDDDK (Flag-tag) G1 Affinity Resin (GenScript, L00432-10) - KL-BsHIV01-003-02, the resulting Flag-KL-BsHIV01-003-02 was digested with enterokinase (nearshore, PE001-01A).
  • Flag-KL-BsHIV01-003-02 before and after digestion was identified by Western blotting with rabbit Anti-KL-BsHIV01-003-02 or mouse Anti-DYKDDDDK (GenScript, A00187-100) ( Figure 9).
  • the results of Western blotting confirmed that the HIV neutralizing antibody KL-BsHIV01-003-02 carrying Flag-tag or not carrying Flag-tag was expressed in the cells and secreted into the supernatant, and had a molecular weight consistent with the prediction.
  • TZM-bl cells were plated at 2E4 cells/well. Mix the purified antibody dilution with 50 ⁇ L of HIV pAD-8 or pNL4-3, incubate at 37°C for 30 minutes, and add to TZM-bl cells. The wells with only pAD-8 or pNL4-3 are negative controls. Wells without HIV virus were blank. After culturing for 24 hours, discard the supernatant, add 100 ⁇ L of cell lysate, collect the lysed cells after 10 minutes, and centrifuge at 8000 rpm for 5 minutes. Add 100 ⁇ L of firefly luciferase assay reagent to 50 ⁇ L of lysed cells.
  • AAV gene therapy vector (pAAV-CBH-KL-BsHIV01-003--02WPRE) were injected intramuscularly into the femoral muscle of the mouse hindlimb. Blood was drawn at regular intervals to separate the serum.
  • ELISA was used to detect the concentration of antibodies expressed in serum. Coat the ELISA plate (Corning, Cat. No.: 42592) with the synthetic HIV MPER polypeptide, express the supernatant and purify and quantify the KL-BsHIV01-003-02 standard as the primary antibody, and use the rabbit anti-HIV membrane fusion inhibition short peptide
  • the polyclonal antibody was used as the secondary antibody, and HRP-labeled goat anti-rabbit IgG (KPL, 5220-0283) was used as the tertiary antibody. The color was developed with TMB, and the OD value at 450nm was detected by a microplate reader.
  • the results of ELISA ( FIG. 11 ) show that the anti-HIV neutralizing antibody adeno-associated virus vector can continuously and effectively express HIV neutralizing antibody in mice.
  • TZM-bl cells at 2E4 cells/well. Mix the 200-fold serum dilution with 50 ⁇ L of HIV virus strain pNL4-3, incubate at 37°C for 30 minutes, and add to TZM-bl cells. The wells with only pNL4-3 are negative controls, and the wells without HIV virus For Blank. After culturing overnight, discard the supernatant, add 100 ⁇ L of cell lysate, collect the lysed cells after 10 min, and centrifuge at 8000 rpm for 5 min. Add 100 ⁇ L of firefly luciferase assay reagent to 50 ⁇ L of lysed cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/CN2022/115831 2021-08-30 2022-08-30 一种用于艾滋病病毒感染基因治疗的基因序列构建体 Ceased WO2023030315A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA3230810A CA3230810A1 (en) 2021-08-30 2022-08-30 Gene sequence construct for gene therapy of human immunodeficiency virus infection
CN202280056353.6A CN118382699A (zh) 2021-08-30 2022-08-30 一种用于艾滋病病毒感染基因治疗的基因序列构建体
JP2024513543A JP2024532453A (ja) 2021-08-30 2022-08-30 エイズウイルス感染の遺伝子治療用の遺伝子配列構築体
US18/687,689 US20240352096A1 (en) 2021-08-30 2022-08-30 Gene sequence construct for gene therapy of human immunodeficiency virus infection
AU2022337765A AU2022337765A1 (en) 2021-08-30 2022-08-30 Gene sequence construct for gene therapy of human immunodeficiency virus infection
EP22863450.7A EP4397764A4 (en) 2021-08-30 2022-08-30 GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021115422 2021-08-30
CNPCT/CN2021/115422 2021-08-30

Publications (1)

Publication Number Publication Date
WO2023030315A1 true WO2023030315A1 (zh) 2023-03-09

Family

ID=85410861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/115831 Ceased WO2023030315A1 (zh) 2021-08-30 2022-08-30 一种用于艾滋病病毒感染基因治疗的基因序列构建体

Country Status (7)

Country Link
US (1) US20240352096A1 (https=)
EP (1) EP4397764A4 (https=)
JP (1) JP2024532453A (https=)
CN (1) CN118382699A (https=)
AU (1) AU2022337765A1 (https=)
CA (1) CA3230810A1 (https=)
WO (1) WO2023030315A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025081292A1 (zh) * 2023-10-16 2025-04-24 北京脑科学与类脑研究所 纳米抗体辅助的蛋白或多肽表达系统及制备和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12611466B2 (en) * 2022-08-29 2026-04-28 Shanghai Ophthal-Bright Biomedicine Technology Modified vector, construction method, and application of modified AAV-8 serotype for gene targeting and expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101500615A (zh) * 2006-08-17 2009-08-05 霍夫曼-拉罗奇有限公司 针对ccr5的抗体和抗融合肽的缀合物
CN102883740A (zh) * 2010-05-03 2013-01-16 纽约血库公司 用于使hiv失活并阻断hiv的双功能分子
CN103282385A (zh) * 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
CN104004092A (zh) * 2014-06-05 2014-08-27 深圳市第三人民医院 单基因编码的双或多价特异性抗hiv免疫粘附素
CN111405910A (zh) * 2017-05-10 2020-07-10 阿尔巴朱纳治疗有限公司 具有高HIV抗病毒和免疫调节双重活性的Fc融合蛋白衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7237449B2 (ja) * 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
CN114645066B (zh) * 2020-12-21 2023-08-25 康霖生物科技（杭州）有限公司 一种用于艾滋病基因治疗的核酸构建体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101500615A (zh) * 2006-08-17 2009-08-05 霍夫曼-拉罗奇有限公司 针对ccr5的抗体和抗融合肽的缀合物
CN102883740A (zh) * 2010-05-03 2013-01-16 纽约血库公司 用于使hiv失活并阻断hiv的双功能分子
CN103282385A (zh) * 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
CN104004092A (zh) * 2014-06-05 2014-08-27 深圳市第三人民医院 单基因编码的双或多价特异性抗hiv免疫粘附素
CN111405910A (zh) * 2017-05-10 2020-07-10 阿尔巴朱纳治疗有限公司 具有高HIV抗病毒和免疫调节双重活性的Fc融合蛋白衍生物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FALKENHAGEN ALEXANDER, JOSHI SADHNA: "Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FI T45", MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 7, 1 June 2017 (2017-06-01), US , pages 387 - 395, XP093041703, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2017.04.017 *
HUANG YAOXING; YU JIAN; LANZI ANASTASIA; YAO XIN; ANDREWS CHASITY D.; TSAI LILY; GAJJAR MILI R.; SUN MING; SEAMAN MICHAE: "Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity", CELL, ELSEVIER, AMSTERDAM NL, vol. 165, no. 7, 16 June 2016 (2016-06-16), Amsterdam NL , pages 1621 - 1631, XP029612948, ISSN: 0092-8674, DOI: 10.1016/j.cell.2016.05.024 *
RENXU CHEN, ET AL.: "Grafting Acrylic Polymers from Flat Nickel and Copper Surfaces by Surface-Initiated Atom Transfer Radical Polymerization", LANGMUIR, AMERICAN CHEMICAL SOCIETY, US, vol. 24, no. 13, 29 May 2008 (2008-05-29), US , pages 6889 - 6896, XP055685920, ISSN: 0743-7463, DOI: 10.1021/la800171h *
See also references of EP4397764A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025081292A1 (zh) * 2023-10-16 2025-04-24 北京脑科学与类脑研究所 纳米抗体辅助的蛋白或多肽表达系统及制备和应用

Also Published As

Publication number Publication date
CN118382699A (zh) 2024-07-23
AU2022337765A1 (en) 2024-03-07
JP2024532453A (ja) 2024-09-05
CA3230810A1 (en) 2023-03-09
EP4397764A4 (en) 2025-09-17
US20240352096A1 (en) 2024-10-24
EP4397764A1 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
Saunders et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection
CN107847591B (zh) 多价人免疫缺陷病毒抗原结合分子及其应用
Padte et al. Engineering multi-specific antibodies against HIV-1
WO2022135139A1 (zh) 一种用于艾滋病基因治疗的核酸构建体
CN106459186B (zh) 针对hiv-1 v1v2 env区域的广谱中和性单克隆抗体
Barbian et al. Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas
US20240352096A1 (en) Gene sequence construct for gene therapy of human immunodeficiency virus infection
US20240391981A1 (en) Gene sequence construct for gene therapy for hiv infection
Schnepp et al. Vector-mediated antibody gene transfer for infectious diseases
CN103224559B (zh) 人源hiv广谱中和抗体a16及其相关生物材料与应用
JP2024532453A5 (https=)
CN115925992A (zh) 一种SARS-CoV-2四聚体RBD融合蛋白及其应用
Schnepp et al. Vector‐Mediated In Vivo Antibody Expression
Sholukh et al. Isolation of monoclonal antibodies with predetermined conformational epitope specificity
Liu et al. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16
CN116547535A (zh) 鉴定冠状病毒的交叉反应性抗体的方法
US20230348597A1 (en) Sars-cov-2 therapies
CN103755805B (zh) HIV-1 Env特异性的全人单克隆抗体
US20240254203A1 (en) Antibody-based antivirus compositions and methods of use
CN102190726B (zh) 一种人源HIV抗体的Fab片段及其编码基因与应用
US20240166727A1 (en) Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
EP0581353A1 (en) Monoclonal antibodies to HiV-1 gp120, cell lines producing them and corresponding epitope structures
Li et al. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies
Kim et al. Enhancing HIV-1 neutralization by increasing the local concentration of membrane-proximal external region-directed broadly neutralizing antibodies
Boehme et al. Engineering recombinant reoviruses to display gp41 membrane-proximal external-region epitopes from HIV-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22863450

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280056353.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2022337765

Country of ref document: AU

Ref document number: AU2022337765

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2024513543

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 3230810

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022337765

Country of ref document: AU

Date of ref document: 20220830

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022863450

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022863450

Country of ref document: EP

Effective date: 20240402